Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-α2b therapy for melanoma

Melanoma Research

Volumn 23, Issue 4, 2013, Pages 336-339

  Yune, Sehyo ^a   Jang, Kee Taek ^a   Jung, Seung Min ^a   Kim, Jung Han ^a   Lee, Jeeyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

high 18F fluorodeoxyglucose uptake; high dose interferon 2b therapy; lymphadenopathy; melanoma

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD3 ANTIGEN; FLUORINE 18;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERPLASIA; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAINTENANCE DRUG DOSE; MELANOMA; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; WIDE EXCISION;

DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHATIC DISEASES; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879977107     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283632ca7     Document Type: Article

References (19)

1. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366:1189-1196.
2. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-126.
3. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-2380.
4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-1677.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
6. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3:900-911.
7. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
8. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112:170-180.
9. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164-3171.
10. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:119-134.
11. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, et al. Melanoma. J Natl Compr Canc Netw 2009; 7:250-275.
12. Ridolfi L, Cangini D, Galassi R, Passardi A, Marzullo A, Moretti A, et al. Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma. J Immunother 2008; 31:675-678.
13. Kalkanis D, Kalkanis A, Gomaa O, Paes FM, Sfakianakis GN. F-18 FDG PET positive hilar and mediastinal lymphadenopathy mimicking metastatic disease in a melanoma patient treated with interferon-alpha-2b. Clin Nucl Med 2011; 36:154-155.
14. Cone LA, Brochert A, Schulz K, Stone RA, Kazi A, Greene D. PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma. Clin Nucl Med 2007; 32:793-796.
15. Wilhelmi M, Gubler C, Renner EL, Mullhaupt B. Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease? Swiss Med Wkly 2006; 136:65-67.
16. Hayat AS, Shaikh N, Masood N. Study for frequency and aetiology of lymphadenopathy during combination therapy for chronic hepatitis C (pegylated interferon alpha plus ribavirin) at a tertiary care hospital in Hyderabad. J Pak Med Assoc 2011; 61:986-989.
17. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703-3718.
18. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009; 31:491-501.
19. Hein WR, Supersaxo A. Effect of interferon-alpha-2a on the output of recirculating lymphocytes from single lymph nodes. Immunology 1988; 64:469-474.